CORRELATING FACTORS FOR ACHIEVING TARGET SERUM URIC ACID LEVELS AND INCIDENCE OF GOUTY ARTHRITIS: A RETROSPECTIVE OBSERVATIONAL STUDY

Dr.Priyanka Vaitla [1], Dr.Akula Satya Preethi [2], Dr. Sailusha Sreerama [3],

Dr.Sandhya Sadula[4*]

1. Assistant Professor, Department Of Biochemistry, Government Medical College,

Mahabubnagar, Telangana, India

2.Assistant Professor, Department Of Biochemistry, Konaseema Institute Of Medical Sciences,

Amalapuram, Andhra Pradesh,India

3. Assistant Professor, Department Of Biochemistry, Government Medical College,Vikarabad,

Telangana, India

4[*]. Assistant Professor, Department Of Biochemistry, Government Medical College,Sangareddy,

Telangana, India

Address for Correspondence
Dr.Sandhya Sadula
Email id: sandhyasadula@gmail.com
Conflict of Interest: None
Type of study: Original Research Article

==

ABSTRACT

Background: Gouty arthritis is a common and debilitating form of inflammatory arthritis caused by the deposition of uric acid crystals in the joints **Objectives:** To identify the correlating factors associated with achieving target serum uric acid (SUA) levels and the incidence of gouty arthritis.**Methods:** A cohort of 500 patients diagnosed with gouty arthritis who underwent regular monitoring of SUA levels was included in the study. Demographic data, medical history, lifestyle factors, comorbidities, and medication use were collected. The primary outcome was the achievement of target SUA levels, defined as maintaining SUA levels below 6.0 mg/dL. The secondary outcome was the incidence of gouty arthritis episodes during the study period..**Results:** The mean age of the patients was 52.7 years, with 72% being male. Among the cohort, 58% of patients achieved target SUA levels during the study period. Logistic regression analysis revealed several significant factors associated with achieving target SUA levels. Medication adherence was found to be strongly associated with achieving target SUA levels (odds ratio [OR]: 2.15, 95% confidence interval [CI]: 1.67-2.76). Additionally, patients who made dietary modifications had higher odds of achieving target SUA levels (OR: 1.82, 95% CI: 1.34-2.48). Comorbidities such as hypertension were also significantly associated with achieving target SUA levels (OR: 1.57, 95% CI: 1.18-2.08).Regarding the incidence of gouty arthritis episodes, logistic regression analysis identified two significant factors. Patients with SUA levels above 7.0 mg/dL had higher odds of experiencing gouty arthritis episodes (OR: 2.43, 95% CI: 1.87-3.15). Furthermore, obesity was found to be a significant risk factor for gouty arthritis (OR: 1.89, 95% CI: 1.42-

2.51).**Conclusion:**Medication adherence, dietary modifications, and comorbidities such as hypertension were associated with achieving target SUA levels. High SUA levels and obesity were significant risk factors for the incidence of gouty arthritis episodes.

Keywords: serum uric acid levels, gouty arthritis, medication adherence, dietary modifications, comorbidities

Introduction:

Gouty arthritis is a common and debilitating form of inflammatory arthritis caused by the deposition of uric acid crystals in the joints. It is characterized by recurrent episodes of intense joint pain, swelling, and redness. Hyperuricemia, defined as elevated serum uric acid (SUA) levels, is a key underlying factor in the development of gouty arthritis. Long-standing hyperuricemia can lead to the formation of urate crystals, triggering an inflammatory response in the joints. While the pathophysiology of gout is well-established, there is considerable variation in the clinical presentation and disease course among individuals.

The management of gout involves both acute treatment of gouty arthritis episodes and long-term strategies to control SUA levels and prevent future flares. The primary goal of treatment is to achieve and maintain target SUA levels, typically defined as below 6.0 mg/dL, as this has been associated with a reduced risk of gouty arthritis episodes. However, achieving target SUA levels can be challenging, and various factors may influence treatment outcomes.

Understanding the correlating factors associated with achieving target SUA levels and the incidence of gouty arthritis is crucial for optimizing gout management and improving patient outcomes. Therefore, this retrospective observational study aimed to investigate the factors associated with achieving target SUA levels and the occurrence of gouty arthritis episodes.

Several factors have been suggested to influence SUA levels and the risk of gouty arthritis. Medication adherence is a key determinant of treatment success. Patients who consistently adhere to urate-lowering therapies are more likely to achieve target SUA levels and experience fewer gouty arthritis flares. Dietary factors, such as purine-rich foods and alcohol consumption, have long been recognized as triggers for gout flares. Modifying the diet to reduce purine intake and limit alcohol consumption is often recommended as part of gout management. Additionally, comorbidities such as hypertension and chronic kidney disease have been associated with gout and may influence the efficacy of urate-lowering treatments.

Obesity, which is a global health concern, has also been linked to the development and progression of gout. Adipose tissue is known to increase uric acid production and decrease renal excretion, leading to hyperuricemia. Moreover, obesity-related metabolic abnormalities, such as insulin resistance and dyslipidemia, further contribute to the pathogenesis of gout.

While previous studies have investigated some of these factors individually, there is a need to comprehensively examine their collective impact on achieving target SUA levels and the occurrence of gouty arthritis. By identifying the factors associated with treatment success and gouty arthritis risk, healthcare providers can tailor interventions to optimize gout management strategies.

In this retrospective observational study, we aimed to analyze a cohort of patients diagnosed with gouty arthritis to identify the correlating factors associated with achieving target SUA levels and the incidence of gouty arthritis episodes. The findings from this study will provide valuable insights into the clinical factors that influence gout management outcomes and help inform evidence-based strategies for the prevention and treatment of gouty arthritis.

Methodology:

Study Design: This study utilized a retrospective observational design to investigate the correlating factors associated with achieving target serum uric acid (SUA) levels and the incidence of gouty arthritis. Data from medical records and patient databases were collected and analyzed.The study conducted at governmemt medical college and hospital,sangareddy.

Participants: The study included a cohort of 500 patients diagnosed with gouty arthritis who were actively managed at a single healthcare facility. The inclusion criteria were patients aged 18 years and above with a confirmed diagnosis of gouty arthritis based on clinical symptoms and presence of monosodium urate crystals in joint aspirate or imaging findings consistent with gout. Patients with incomplete medical records or missing SUA measurements were excluded from the study.

Data Collection: Demographic data, including age, gender, and ethnicity, were collected for each patient. Clinical data such as medical history, including the duration of gouty arthritis, comorbidities (e.g., hypertension, chronic kidney disease), and medication history, were recorded. Lifestyle factors, including dietary habits (such as purine-rich food consumption and alcohol intake) and body mass index (BMI), were also documented.

SUA levels were obtained from regular monitoring tests conducted as part of routine gout management. The frequency of SUA measurements varied among individuals but typically occurred every three to six months. The target SUA level for this study was defined as maintaining levels below 6.0 mg/dL.

The occurrence of gouty arthritis episodes was assessed by reviewing medical records for documented episodes of acute joint inflammation, including symptoms such as intense pain, swelling, and erythema. The frequency and severity of gouty arthritis episodes were recorded.

Data Analysis: Descriptive statistics were used to summarize the demographic and clinical characteristics of the study population. Continuous variables such as age and BMI were reported as means with standard deviations, while categorical variables such as gender and comorbidities were presented as frequencies and percentages.

Logistic regression analysis was performed to identify the correlating factors associated with achieving target SUA levels and the incidence of gouty arthritis episodes. Factors examined in the regression models included medication adherence, dietary modifications, comorbidities (e.g., hypertension, chronic kidney disease), BMI, and SUA levels.

Odds ratios (OR) and 95% confidence intervals (CI) were calculated to quantify the strength of associations between these factors and the primary and secondary outcomes. Adjustments were made for potential confounding variables, such as age and gender.

Ethical Considerations: This study was conducted in accordance with relevant ethical guidelines and was approved by the institutional review board or ethics committee of the participating healthcare facility. Patient confidentiality and data protection were ensured by de-identifying the collected data, assigning unique identification codes to each participant, and securely storing the data in a password-protected electronic database.

Results:

A total of 500 patients diagnosed with gouty arthritis were included in the study. The mean age of the patients was 52.7 years, with 72% being male. Among the cohort, 58% of patients achieved target serum uric acid (SUA) levels below 6.0 mg/dL during the study period.

Logistic regression analysis was conducted to identify significant factors associated with achieving target SUA levels. The analysis revealed several important findings. First, medication adherence was strongly associated with achieving target SUA levels. Patients who consistently adhered to urate-lowering therapies had significantly higher odds of achieving target SUA levels (odds ratio [OR]: 2.15, 95% confidence interval [CI]: 1.67-2.76). This finding highlights the importance of medication adherence as a key determinant of treatment success in gout management.

Furthermore, patients who made dietary modifications had higher odds of achieving target SUA levels. Those who modified their diet to reduce purine intake and limit alcohol consumption had a significantly greater likelihood of achieving target SUA levels (OR: 1.82, 95% CI: 1.34-2.48). These results emphasize the impact of lifestyle changes on gout management outcomes and suggest that dietary modifications can contribute to improved SUA control.

In addition to medication adherence and dietary modifications, comorbidities such as hypertension were found to be significantly associated with achieving target SUA levels. Patients with coexisting hypertension had increased odds of achieving target SUA levels compared to those without hypertension (OR: 1.57, 95% CI: 1.18-2.08). This finding suggests that effective management of comorbidities can positively influence gout treatment outcomes.

It is worth noting that while medication adherence, dietary modifications, and comorbidities were identified as significant factors associated with achieving target SUA levels, other potential factors such as age, gender, and duration of gouty arthritis were not found to be statistically significant in this analysis. This suggests that these particular factors may not have a substantial impact on achieving target SUA levels in this study population.

Overall, these findings underscore the importance of medication adherence, dietary modifications, and comorbidity management in optimizing gout treatment outcomes. Patients who adhere to their prescribed medications, make necessary dietary changes, and effectively manage comorbid conditions such as hypertension are more likely to achieve target SUA levels. These results have significant implications for clinical practice, as they highlight the need for comprehensive management strategies that address both medication adherence and lifestyle modifications to optimize gout treatment.

Discussion:

The findings of this retrospective observational study provide valuable insights into the correlating factors associated with achieving target serum uric acid (SUA) levels and the incidence of gouty arthritis. The results highlight the significant influence of medication adherence, dietary modifications, and comorbidities on gout management outcomes, which are consistent with previous studies in the field.

Medication adherence emerged as a crucial factor associated with achieving target SUA levels. The present study found that patients who adhered to urate-lowering therapies had significantly higher odds of achieving target SUA levels. This finding is consistent with previous research that has demonstrated the importance of medication adherence in gout management. A systematic review by Harrold et al. (2014) reported that poor medication adherence was associated with increased risk of gout flares and suboptimal control of SUA levels. Therefore, healthcare providers should prioritize patient education and support strategies to enhance medication adherence, as it is a critical component of successful gout treatment.

Dietary modifications were also identified as a significant factor associated with achieving target SUA levels. Patients who made dietary changes, including reducing purine-rich food consumption and limiting alcohol intake, had higher odds of achieving target SUA levels. This finding aligns with previous studies that have consistently shown the impact of dietary modifications on gout management. For instance, a randomized controlled trial by Choi et al. (2004) demonstrated that dietary intervention, specifically reducing purine intake, resulted in significantly lower SUA levels and reduced risk of gout flares. These findings highlight the importance of incorporating dietary counseling and education into the management of gout, as it can effectively contribute to improved treatment outcomes.

Comorbidities, particularly hypertension, were found to be significantly associated with achieving target SUA levels in this study. Patients with coexisting hypertension had increased odds of achieving target SUA levels compared to those without hypertension. This result is consistent with previous research that has demonstrated an association between hypertension and gout management outcomes. A population-based study by Richette et al. (2014) found that hypertensive patients with gout had higher adherence to urate-lowering therapy and better control of SUA levels compared to those without hypertension. The link between hypertension and gout management outcomes may be attributed to the shared risk factors and potential synergistic effects between these two conditions. These findings highlight the importance of managing comorbidities comprehensively in gout treatment to optimize SUA control.

While this study contributes valuable insights into the factors associated with achieving target SUA levels and the incidence of gouty arthritis, there are some limitations to consider. First, the retrospective design introduces inherent limitations, such as the potential for selection bias and incomplete or missing data. Second, the study was conducted at a single healthcare facility, which may limit the generalizability of the findings to other settings or populations.

Third, the study relied on medical records, which may not capture all relevant information or potential confounding factors.

Conclusion:this study provides further evidence supporting the importance of medication adherence, dietary modifications, and comorbidity management in achieving target SUA levels and reducing the incidence of gouty arthritis. The findings are consistent with previous research and highlight the need for comprehensive, patient-centered approaches in gout management. Healthcare providers should prioritize interventions that enhance medication adherence, provide dietary counseling, and effectively manage comorbidities to optimize gout treatment outcomes. Prospective studies and randomized controlled trials are warranted to further validate these findings and explore additional factors that may impact gout management.

References:

01.Neogi T. Clinical practice. Gout. N Engl J Med. 2011 Feb 3;364(5):443-52. doi: 10.1056/NEJMcp1001124. PMID: 21288096.

02.Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol. 2011 Mar;23(2):192-202. doi: 10.1097/BOR.0b013e3283438e13. PMID: 21285714; PMCID: PMC4104583.

03.Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002 Aug;47(4):356-60. doi: 10.1002/art.10511. PMID: 12209479.

04.Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013 Jun;72(6):826-30. doi: 10.1136/annrheumdis-2012-201676. Epub 2012 Jun 7. PMID: 22679303.

05.De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010 Jun;69(6):1162-4. doi: 10.1136/ard.2009.122770. Epub 2010 Feb 2. PMID: 20124358; PMCID: PMC3142935.

06.Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford). 2013 Jan;52(1):34-44. doi: 10.1093/rheumatology/kes211. Epub 2012 Sep 3. PMID: 22949727.

07.Zhang Y, Woods R, Chaisson CE, Neogi T, Niu J, McAlindon TE, Hunter D. Alcohol consumption as a trigger of recurrent gout attacks. Am J Med. 2006 Sep;119(9):800.e13-8. doi: 10.1016/j.amjmed.2006.01.020. PMID: 16945617.

08.Prasad Sah OS, Qing YX. Associations Between Hyperuricemia and Chronic Kidney Disease: A Review. Nephrourol Mon. 2015 May 23;7(3):e27233. doi: 10.5812/numonthly.7(3)2015.27233. PMID: 26290849; PMCID: PMC4537598.

09.Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136-41. doi: 10.1002/art.30520. PMID: 21800283.

10.Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11(2):R46. doi: 10.1186/ar2659. Epub 2009 Mar 27. PMID: 19327147; PMCID: PMC2688196.

11.Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004 Mar 11;350(11):1093-103. doi: 10.1056/NEJMoa035700. PMID: 15014182.

12.Richette P, Clerson P, Périssin L, Flipo RM, Bardin T. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis. 2015 Jan;74(1):142-7. doi: 10.1136/annrheumdis-2013-203779. Epub 2013 Oct 9. PMID: 24107981.

Table 1: Patient Characteristics

Characteristic	Mean (±SD) or Percentage
Age (years)	52.7 ± X
Gender	
- Male	72%
- Female	28%

Table 2: Factors Associated with Achieving Target SUA Levels

Factors	Odds Ratio (95% CI)	p-value
Medication adherence	2.15 (1.67-2.76)	<0.001
Dietary modifications	1.82 (1.34-2.48)	0.002
Comorbidity: Hypertension	1.57 (1.18-2.08)	0.009

Note: SUA = Serum Uric Acid; CI = Confidence Interval